» Articles » PMID: 30352078

Metabolic Reprogramming by Dichloroacetic Acid Potentiates Photodynamic Therapy of Human Breast Adenocarcinoma MCF-7 Cells

Overview
Journal PLoS One
Date 2018 Oct 24
PMID 30352078
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Aberrant glycolytic metabolism is one of the hallmarks of carcinogenesis and therefore reversal of metabolic transformation is a promising drug target in cancer treatment strategies. Dichloroacetic acid (DCA) is known to target the glycolytic pathway in cancer cells and facilitates reversal of metabolic transformation from aerobic cytosolic accumulation of pyruvic acid, "the Warburg effect", to mitochondrial oxidative phosphorylation. Recently, combination therapy particularly involving photodynamic therapy (PDT) has received considerable attention in oncology. We hypothesized that if DCA and PDT are combined, they might potentiate mitochondrial dysfunction and induce apoptosis by a reactive oxygen species (ROS) dependent pathway. We used MCF-7 cells as our in vitro model and 5-aminolevulinic acid (5-ALA) dependent PDT therapy to test our hypothesis. We found that combinatorial treatment of MCF-7 cells with PDT and DCA not only increased cell growth inhibition, but also affected mitochondrial membrane integrity perhaps via production of ROS, and enhanced apoptosis. Further, our results on ATP release during the combined treatment demonstrate that immunogenic cell death (ICD) is likely to be a potential mechanism by which PDT and DCA induce cancer cell death. Taken together, our study suggests a novel way of sensitizing MCF-7 cells for accelerated induction of apoptosis and ICD in these cells. The findings included in this study might have direct relevance in breast cancer treatment strategies.

Citing Articles

Encapsulation of Inositol Hexakisphosphate with Chitosan via Gelation to Facilitate Cellular Delivery and Programmed Cell Death in Human Breast Cancer Cells.

Kadhim I, Oluremi A, Chhetri B, Ghosh A, Ali N Bioengineering (Basel). 2024; 11(9).

PMID: 39329673 PMC: 11429465. DOI: 10.3390/bioengineering11090931.


Modulating Glycolysis to Improve Cancer Therapy.

Chelakkot C, Chelakkot V, Shin Y, Song K Int J Mol Sci. 2023; 24(3).

PMID: 36768924 PMC: 9916680. DOI: 10.3390/ijms24032606.


Dichloroacetate and PX-478 exhibit strong synergistic effects in a various number of cancer cell lines.

Parczyk J, Ruhnau J, Pelz C, Schilling M, Wu H, Piaskowski N BMC Cancer. 2021; 21(1):481.

PMID: 33931028 PMC: 8086110. DOI: 10.1186/s12885-021-08186-9.


In order for the light to shine so brightly, the darkness must be present-why do cancers fluoresce with 5-aminolaevulinic acid?.

McNicholas K, MacGregor M, Gleadle J Br J Cancer. 2019; 121(8):631-639.

PMID: 31406300 PMC: 6889380. DOI: 10.1038/s41416-019-0516-4.


Mitochondrial Flexibility of Breast Cancers: A Growth Advantage and a Therapeutic Opportunity.

Avagliano A, Ruocco M, Aliotta F, Belviso I, Accurso A, Masone S Cells. 2019; 8(5).

PMID: 31052256 PMC: 6562467. DOI: 10.3390/cells8050401.

References
1.
Hodge J, Guha C, Neefjes J, Gulley J . Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park). 2008; 22(9):1064-70. PMC: 3474236. View

2.
Ribas A . Releasing the Brakes on Cancer Immunotherapy. N Engl J Med. 2015; 373(16):1490-2. DOI: 10.1056/NEJMp1510079. View

3.
Garg A, Krysko D, Verfaillie T, Kaczmarek A, Ferreira G, Marysael T . A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 2012; 31(5):1062-79. PMC: 3298003. DOI: 10.1038/emboj.2011.497. View

4.
Chen G, Emens L . Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother. 2013; 62(2):203-16. PMC: 3608094. DOI: 10.1007/s00262-012-1388-0. View

5.
Mahoney K, Rennert P, Freeman G . Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015; 14(8):561-84. DOI: 10.1038/nrd4591. View